MAXCYTE INC

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(in thousands)


· Year Ended December 31, ·
· · 2024 · 2023 ·
Cash flows from operating activities: · ·
Net loss	$(41,055)	$(37,923)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,315	4,171
Lease right-of-use asset amortization	475	395
Net book value of consigned equipment sold	63	94
Loss on disposal of property and equipment	861	30
Stock-based compensation	13,083	13,979
Credit loss (recovery) expense	(130)	171
Change in excess/obsolete inventory reserve	1,771	697
Amortization of discounts on investments	(6,242)	(7,120)

Changes in operating assets and liabilities:
Accounts receivable	1,226	5,226
Accounts receivable - TIA	—	1,912
Inventory	1,362	(4,534)
Prepaid expense and other current assets	293	(641)
Other assets	(1,213)	421
Accounts payable, accrued expenses and other	(1,883)	3,252
Operating lease liability	(709)	(133)
Deferred revenue	182	(1,644)
Other liabilities	(9)	(39)
Net cash used in operating activities	(27,610)	(21,686)

Cash flows from investing activities:
Purchases of investments	(150,857)	(255,095)
Maturities of investments	159,440	313,770
Purchases of property and equipment	(1,651)	(3,700)
Proceeds from sale of equipment	—	9
Net cash provided by investing activities	6,932	54,984

Cash flows from financing activities:
Proceeds from exercise of stock options	1,597	1,874
Proceeds from issuance of common stock under employee stock purchase plan	459	269
Net cash provided by financing activities	2,056	2,143
Net (decrease) increase in cash and cash equivalents	(18,622)	35,441
Cash and cash equivalents, beginning of period	46,506	11,065
Cash and cash equivalents, end of period	$27,884	$46,506

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	$97	$566
Right-of-use assets obtained in exchange for lease liabilities	$—	$1,782

MaxCyte, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.